NO944923L - Hemming av vektökning eller indusering av vekttap - Google Patents
Hemming av vektökning eller indusering av vekttapInfo
- Publication number
- NO944923L NO944923L NO944923A NO944923A NO944923L NO 944923 L NO944923 L NO 944923L NO 944923 A NO944923 A NO 944923A NO 944923 A NO944923 A NO 944923A NO 944923 L NO944923 L NO 944923L
- Authority
- NO
- Norway
- Prior art keywords
- weight
- inhibition
- induction
- weight loss
- weight gain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/171,291 US5578613A (en) | 1993-12-21 | 1993-12-21 | Methods for inhibiting weight gain or inducing weight loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO944923D0 NO944923D0 (no) | 1994-12-19 |
| NO944923L true NO944923L (no) | 1995-06-22 |
Family
ID=22623225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944923A NO944923L (no) | 1993-12-21 | 1994-12-19 | Hemming av vektökning eller indusering av vekttap |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5578613A (ja) |
| EP (1) | EP0659423A1 (ja) |
| JP (1) | JPH07196492A (ja) |
| KR (1) | KR950016741A (ja) |
| CN (1) | CN1107707A (ja) |
| AU (1) | AU8154094A (ja) |
| CA (1) | CA2138455A1 (ja) |
| CZ (1) | CZ322294A3 (ja) |
| HU (1) | HUT71342A (ja) |
| IL (1) | IL112044A (ja) |
| NO (1) | NO944923L (ja) |
| NZ (1) | NZ270182A (ja) |
| PH (1) | PH31266A (ja) |
| RU (1) | RU94044357A (ja) |
| TW (1) | TW272126B (ja) |
| ZA (1) | ZA9410090B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
| KR20010052891A (ko) | 1998-06-16 | 2001-06-25 | 피터 지. 스트링거 | 아세틸콜린 수치를 상승시키는 방법 |
| ATE301129T1 (de) | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
| US20060088860A1 (en) * | 2004-09-13 | 2006-04-27 | Lipomics Technologies, Inc. | Metabolite markers for weight management |
| CA2588087A1 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| CA2707549A1 (en) | 2007-12-03 | 2009-06-11 | Itzik Harosh | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
| WO2013102207A1 (en) * | 2011-12-30 | 2013-07-04 | Rosscreening, Inc. | Estrogen receptor modulators for reducing body weight |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| TW303299B (ja) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli |
-
1993
- 1993-12-21 US US08/171,291 patent/US5578613A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 CZ CZ943222A patent/CZ322294A3/cs unknown
- 1994-12-19 RU RU94044357/14A patent/RU94044357A/ru unknown
- 1994-12-19 CA CA002138455A patent/CA2138455A1/en not_active Abandoned
- 1994-12-19 PH PH49576A patent/PH31266A/en unknown
- 1994-12-19 AU AU81540/94A patent/AU8154094A/en not_active Abandoned
- 1994-12-19 NZ NZ270182A patent/NZ270182A/en unknown
- 1994-12-19 EP EP94309481A patent/EP0659423A1/en not_active Withdrawn
- 1994-12-19 IL IL11204494A patent/IL112044A/en not_active IP Right Cessation
- 1994-12-19 TW TW083111849A patent/TW272126B/zh active
- 1994-12-19 KR KR1019940034932A patent/KR950016741A/ko not_active Application Discontinuation
- 1994-12-19 HU HU9403673A patent/HUT71342A/hu unknown
- 1994-12-19 JP JP6314559A patent/JPH07196492A/ja active Pending
- 1994-12-19 CN CN94119748A patent/CN1107707A/zh active Pending
- 1994-12-19 ZA ZA9410090A patent/ZA9410090B/xx unknown
- 1994-12-19 NO NO944923A patent/NO944923L/no unknown
-
1995
- 1995-03-15 US US08/404,854 patent/US5578614A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU8154094A (en) | 1995-06-29 |
| RU94044357A (ru) | 1996-10-20 |
| IL112044A (en) | 1999-01-26 |
| US5578613A (en) | 1996-11-26 |
| HUT71342A (en) | 1995-11-28 |
| IL112044A0 (en) | 1995-03-15 |
| HU9403673D0 (en) | 1995-02-28 |
| CA2138455A1 (en) | 1995-06-22 |
| US5578614A (en) | 1996-11-26 |
| ZA9410090B (en) | 1996-06-19 |
| EP0659423A1 (en) | 1995-06-28 |
| CZ322294A3 (en) | 1995-09-13 |
| NO944923D0 (no) | 1994-12-19 |
| CN1107707A (zh) | 1995-09-06 |
| JPH07196492A (ja) | 1995-08-01 |
| NZ270182A (en) | 1996-08-27 |
| PH31266A (en) | 1998-06-18 |
| KR950016741A (ko) | 1995-07-20 |
| TW272126B (ja) | 1996-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944911L (no) | Ikke-peptid-takykininreseptorantagonister | |
| NO944928L (no) | Fremgangsmåter for inhibering av Alzheimers sykdom | |
| DE69430465D1 (de) | Hemmung uteriner Fibrose | |
| NO944934L (no) | Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom | |
| ATE260104T1 (de) | Hemmung der endprodukte fortgeschrittener glykolisierung | |
| NO944923L (no) | Hemming av vektökning eller indusering av vekttap | |
| NO944930L (no) | Hemming av dysfunksjonell uterin blödning | |
| NO943873L (no) | Hemming av bruskdegradering | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
| NO944917D0 (no) | Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme | |
| NO944931L (no) | Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet | |
| NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
| NO944577L (no) | Hemming av effekten av amyloidogene proteiner | |
| NO971794L (no) | Fremgangsmåte for hemming av tilstander forbundet med bradykinin | |
| NO944909L (no) | Fremgangsmåter for inhibering av mannlig infertilitet | |
| NO970783L (no) | Fremgangsmåte for å hindre endometrialkreft | |
| NO973103L (no) | Fremgangsmåte for inhibering av veksthormoneffekter | |
| NO944910L (no) | Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser | |
| NO944912L (no) | Fremgangsmåte for å öke makrofagfunksjonen | |
| ATE63309T1 (de) | 2,3-dihydro-2-oxo-3-benzofuranylessigs|urederivate und diese enthaltende arzneimittel. | |
| FI970716A (fi) | Menetelmiä primaarisen kohdun limakalvon liikakasvun estämiseksi | |
| JPS5430167A (en) | 4-aminomethyl-2-phenyloxazoles and their pharmaceutically acceptable acid salts | |
| NO973470L (no) | Fremgangsmåte for minsking av serumkalsiumnivåer |